OncoCyte (NAS:OCX) Earnings per Share (Diluted)

: $-0.65 (TTM As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

OncoCyte's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.65.

OncoCyte's EPS (Basic) for the three months ended in Sep. 2022 was $-0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.65.

OncoCyte's EPS without NRI for the three months ended in Sep. 2022 was $-0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.65.

OncoCyte Earnings per Share (Diluted) Historical Data

The historical data trend for OncoCyte's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Earnings per Share (Diluted)

-0.64

-0.42

-0.44

-0.46

-0.72

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Earnings per Share (Diluted)																-0.15	-0.39	-0.11	-0.07	-0.08

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Earnings per Share (Diluted), along with its competitors' market caps and Earnings per Share (Diluted) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

OncoCyte Earnings per Share (Diluted) Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Earnings per Share (Diluted) distribution charts can be found below:

* The bar in red indicates where OncoCyte's Earnings per Share (Diluted) falls in comparison to its industry or sector. The grey bar indicates the Earnings per Share (Diluted)'s extreme value range as defined by GuruFocus.

OncoCyte Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

OncoCyte's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-64.097	-	0)	/	88.920
	=	-0.72

OncoCyte's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2022 is calculated as

Diluted Earnings Per Share (Q: Sep. 2022 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-9.333	-	0)	/	118.610
	=	-0.08

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

OncoCyte (NAS:OCX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

OncoCyte Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of OncoCyte's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund	director	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen	officer: Chief Operating Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross	officer: Chief Medical Officer	15 CUSHING, IRVINE CA 92618
Tony T Kalajian	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008